Gupta, a professor at the University of Washington's Institute for Health Metrics and Evaluation, told "The News with Shepard Smith" that "AstraZeneca, when combined with a Pfizer or Moderna booster, is showing tremendous levels of protection against delta, in terms of the antibody levels that are generated in patients."
"I do think that those one-shot J&Jer's should be given the opportunity, while we complete our clinical trial ... I'm already telling my patients to do it, if they can get access to it."
Gupta's comments come on the heels of a new study from a lab at New York University Tuesday that raises serious questions about the effectiveness of J&J's single-dose vaccine against the highly contagious delta variant. The NYU study is not yet peer reviewed, but found that the antibody levels in those who received the J&J shot may be low enough to be less protective.